


## Tr-PEG2-OH

<b>Cat. No.:</b>	HY-114995		
<b>CAS No.:</b>	105589-77-3		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>24</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	348.43		
<b>Target:</b>	ADC Linker; PROTAC Linkers		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tr-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Tr-PEG2-OH is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[2]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	Non-cleavable	PEGs	
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

- [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562.
- [2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov*. 2017 May;16(5):315-337.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA